Meropenem

Reading File

Finding Sources

Searching PubMed

meropenem carbapenem

Reading File

Finding Sources

Reading File

I now have comprehensive information from multiple authoritative textbooks. Here is a full, structured overview of Meropenem:

Meropenem

Drug Class & Structure

Meropenem is a carbapenem beta-lactam antibiotic - a derivative of thienamycin. Carbapenems contain a fused beta-lactam ring with a five-membered ring system that is unsaturated and has a carbon atom (instead of sulfur as in penicillins). This structural difference confers greater resistance to beta-lactamase hydrolysis compared to other beta-lactams.

Unlike imipenem, meropenem does not require co-administration with cilastatin because it is not susceptible to renal dipeptidase (dehydropeptidase) degradation.

Goodman & Gilman's, p. 1009

Mechanism of Action

Meropenem, like all beta-lactams, works by:

Binding to Penicillin-Binding Proteins (PBPs) on the bacterial cell membrane
Inhibiting transpeptidation - disrupting cross-linking of peptidoglycan in the bacterial cell wall
Leading to cell lysis and death of susceptible organisms

It is highly resistant to hydrolysis by most beta-lactamases (serine and extended-spectrum beta-lactamases), but is degraded by carbapenemases (KPC, NDM, OXA).

Spectrum of Activity

Meropenem has one of the broadest antibacterial spectra of any antibiotic:

Category	Coverage
Gram-positive	Streptococci, S. pneumoniae (including penicillin-resistant), Staphylococci (not MRSA), Listeria; less active than imipenem against Enterococcus
Gram-negative aerobes	Enterobacterales (E. coli, Klebsiella, Enterobacter, Proteus, Serratia), Pseudomonas aeruginosa, Acinetobacter spp. - more active than imipenem
Anaerobes	Bacteroides fragilis and other anaerobes - highly susceptible
Not covered	MRSA, Enterococcus faecium, Clostridioides difficile, Burkholderia cepacia, Stenotrophomonas maltophilia, carbapenemase-producing organisms

Key distinction from imipenem: Meropenem is somewhat less active against gram-positives (especially Enterococcus) but more active against gram-negatives (especially Pseudomonas).

Goodman & Gilman's, p. 1011; Katzung's Pharmacology, p. 1343

Pharmacokinetics (ADME)

Administration: IV only (not orally absorbed)
Half-life: ~1 hour
Clearance: Renally cleared - dose reduction required in renal insufficiency
CSF penetration: Good - penetrates the CNS (unlike ertapenem), making it suitable for meningitis
Standard infusion: 30 minutes IV

Extended infusion strategy: Infusing over 3 hours (instead of 30 minutes) increases the time that meropenem concentrations spend above the organism's MIC (%T>MIC), which is the key pharmacodynamic parameter for beta-lactams. This allows treatment of pathogens with low-level resistance.

Goodman & Gilman's, p. 1013; Katzung's, p. 1349

Dosing

Indication	Dose
Standard (normal renal function)	1-2 g IV every 8 hours
Mild-moderate infections	0.5-1 g IV q8h
Meningitis / severe infections	2 g IV q8h
Meropenem/vaborbactam	2 g meropenem + 2 g vaborbactam IV q8h (3-hour infusion)

Dose must be adjusted for renal impairment (creatinine clearance).

Adverse Effects

Meropenem is generally well tolerated. Key adverse effects:

Nausea and vomiting (1-20%) - similar to imipenem
Seizures - can occur but less likely than with imipenem; this is why meropenem is the preferred carbapenem for CNS infections/meningitis
Drug interaction - Valproic acid: Meropenem (and other carbapenems) significantly lowers serum concentrations of valproic acid - these should NOT be co-administered. This is a clinically important interaction
Hypersensitivity/cross-reactivity with other beta-lactams (generally safe in penicillin-allergic patients except severe immediate-type reactions)

Goodman & Gilman's, p. 1013

Therapeutic Uses

Meropenem is primarily reserved for serious hospital-acquired infections or infections caused by resistant pathogens:

Nosocomial pneumonia / VAP - especially when Pseudomonas or Acinetobacter are suspected
Intra-abdominal infections (complicated, polymicrobial)
Urinary tract infections - caused by resistant organisms (ESBL-producers, CRE)
CNS infections / meningitis - preferred carbapenem (over imipenem) due to lower seizure risk
Sepsis/bacteremia of unknown source in critically ill patients at risk for MDR organisms
Skin, soft tissue, bone, and joint infections - caused by resistant organisms
ESBL-producing Enterobacterales - carbapenems are the treatment of choice
Febrile neutropenia in immunocompromised patients

Meropenem/Vaborbactam (Vabomere)

Vaborbactam is a boronic acid beta-lactamase inhibitor that restores meropenem's activity against:

Carbapenemase-producing Enterobacterales (particularly KPC-producers)
Some carbapenem-resistant organisms

Does NOT cover metallo-beta-lactamase producers (NDM, VIM, IMP).

Reserved for multidrug-resistant gram-negative infections such as CRE UTI, pyelonephritis, hospital-acquired/ventilator-associated pneumonia.

Goodman & Gilman's, p. 1011, 1015; Katzung's, p. 1342

Resistance Mechanisms

Organisms can resist meropenem via:

Carbapenemases (most clinically significant):
- Class A (KPC - Klebsiella pneumoniae carbapenemase): Serine-based, common in Enterobacterales
- Class B (Metallo-beta-lactamases - NDM, VIM, IMP): Zinc-dependent; resistant to all beta-lactams and not overcome by most BLIs
- Class D (OXA carbapenemases): Primarily in Acinetobacter; often pan-resistant
Porin loss (OmpK35/36 in Klebsiella) - reduced drug entry
Efflux pump overexpression - particularly in Pseudomonas (MexAB-OprM)

Medical Microbiology 9e, p. 1699

Key Comparisons Within Carbapenems

Feature	Meropenem	Imipenem	Ertapenem
Cilastatin needed	No	Yes	No
Gram-positive activity	+	++	+
Gram-negative activity	++	+	+
Pseudomonas coverage	Yes	Yes	No
Acinetobacter coverage	Yes	Yes	No
CNS use (meningitis)	Preferred	Avoid (seizures)	No (no CNS penetration)
Dosing	q8h	q6-8h	Once daily
t1/2	~1 h	~1 h	~4 h

Recent Evidence Update

A 2024 systematic review on PK/PD of novel beta-lactams for carbapenem-resistant gram-negative pneumonia (PMID: 38971203) highlights meropenem/vaborbactam as a key agent in the treatment landscape of carbapenem-resistant organisms. A 2024 network meta-analysis (PMID: 39533846) confirmed that combining vancomycin with meropenem (vs. piperacillin/tazobactam) carries a lower risk of acute kidney injury, reinforcing meropenem as the safer combination partner.

Sources:

Goodman & Gilman's Pharmacological Basis of Therapeutics - Meropenem section
Katzung's Basic and Clinical Pharmacology, 16th ed. - Carbapenems
Medical Microbiology 9e - Carbapenems and resistance
The Washington Manual of Medical Therapeutics - Clinical use

How do I remember so much info easily?

Here are the most effective, evidence-backed strategies for retaining large amounts of information:

1. Spaced Repetition (Most Powerful)

Instead of re-reading notes, review information at increasing intervals - just before you're about to forget it.

Day 1 → Day 3 → Day 7 → Day 14 → Day 30
Tools: Anki (free flashcard app) automates this for you
This single technique has the strongest evidence behind it for long-term retention

2. Active Recall Over Passive Reading

Testing yourself is far more effective than re-reading or highlighting.

Close your notes and try to write/say everything you know about a topic
Answer questions before looking at the answer
The struggle to retrieve information is what strengthens the memory

3. Build Mental Frameworks (Chunking)

Your brain remembers structure, not random facts. For something like meropenem:

Anchor everything to a skeleton: Class → Mechanism → Spectrum → PK → Dosing → ADRs → Uses
Once the skeleton is memorized, you hang facts onto it like branches
Compare and contrast (meropenem vs. imipenem vs. ertapenem) - relationships reinforce memory

4. Mnemonics & Stories

For lists or sequences that don't have inherent logic:

Create an acronym, rhyme, or absurd story
Example for carbapenem resistance gaps: "Mr. BECS" - Burkholderia, Enterococcus faecium, C. difficile, Stenotrophomonas
The weirder/more vivid the image, the better it sticks

5. Understand, Don't Memorize

Facts that make mechanistic sense are far easier to retain:

"Meropenem doesn't need cilastatin" - because once you know why (it's not degraded by renal dipeptidase), you'll never forget it
"Preferred for meningitis over imipenem" - because you understand it causes fewer seizures
Ask "why?" constantly - understanding creates memory automatically

6. Interleaving

Instead of studying one topic exhaustively (blocked practice), mix topics in your study sessions:

E.g., carbapenems → glycopeptides → aminoglycosides → back to carbapenems
Feels harder in the moment, but produces significantly stronger long-term recall

7. Sleep & Exercise

Sleep is when your brain consolidates memories - cramming before sleep works, pulling all-nighters doesn't
Aerobic exercise (even 20 min) increases BDNF (brain-derived neurotrophic factor), which directly enhances memory formation

8. Teach It (Feynman Technique)

Explain a concept out loud as if teaching a 12-year-old. Gaps in your explanation reveal exactly what you don't actually understand yet. Fix those gaps, then teach it again.

For Medical/Pharmacology Content Specifically

Strategy	Application
Anki decks	Pre-made medical decks (Zanki, AnKing) cover pharmacology extensively
Sketchy / Picmonic	Visual story-based mnemonics for drugs and micro
First Aid framework	Standardized skeleton for every drug class
Clinical context	Attaching a drug to a real or imagined patient makes it memorable

The honest answer: there's no shortcut to volume - but spaced repetition + active recall + understanding the why will get you 80% of the way there with a fraction of the time passive re-reading requires.

This is a shared conversation. Sign in to Orris to start your own chat.